Akero Therapeutics, Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Dec. 29, 2023).
In: Drug Week, 2024-01-19, S. 2927
serialPeriodical
Zugriff:
Akero Therapeutics, Inc. has filed a Form 4 with the U.S. Securities and Exchange Commission (SEC) on December 29, 2023. The company's SIC code is 2834, Pharmaceutical Preparations. The filing is a statement of changes in beneficial ownership of securities, which is required for directors, officers, or owners of more than ten percent of a class of equity securities. The SEC filing is a formal document or financial statement submitted by publicly-traded companies. For more information, the SEC filing can be found at the provided link. [Extracted from the article]
Copyright of Drug Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Akero Therapeutics, Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Dec. 29, 2023).
|
---|---|
Zeitschrift: | Drug Week, 2024-01-19, S. 2927 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1531-6440 (print) |
Sonstiges: |
|